Berkeley Haas Case Series

Case Information

Napo Pharmaceuticals: Triple Bottom Line of People, Planet, and Profits (A)
Raube, Kristiana
Publication date: 2/14/2014, pages 1-15

The Napo Pharmaceuticals case provides students with an example of a biotech company that pursued a triple bottom line of people, planet, and profit while making life-saving drugs like crofelemer to deal with diarrhea in adult HIV/AIDS patients and potentially diarrhea for children around the world. The case focuses on CEO and founder, Lisa Conte's challenging road to the point where they achieved FDA approval for the drug. It also outlines the issues such mission-oriented biotech companies faced in the more typical profit-oriented world of biotech. Please note: This case also has a (B) supplement available.

Educators may request a complimentary preview before purchasing. To find out more, please read about our publishing partnerships.

To request permission, please submit a Copyright Permission Request Form.